Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death.

Vuillier C, Lohard S, Fétiveau A, Allègre J, Kayaci C, King LE, Braun F, Barillé-Nion S, Gautier F, Dubrez L, Gilmore AP, Juin PP, Maillet L.

EMBO Rep. 2018 Feb;19(2):234-243. doi: 10.15252/embr.201744046. Epub 2017 Dec 12.

PMID:
29233828
2.

BCL-XL directly modulates RAS signalling to favour cancer cell stemness.

Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP.

Nat Commun. 2017 Oct 24;8(1):1123. doi: 10.1038/s41467-017-01079-1.

3.

13C and 15N natural isotope abundance reflects breast cancer cell metabolism.

Tea I, Martineau E, Antheaume I, Lalande J, Mauve C, Gilard F, Barillé-Nion S, Blackburn AC, Tcherkez G.

Sci Rep. 2016 Sep 28;6:34251. doi: 10.1038/srep34251.

4.

A Ring-D-Seco-Tetranortriterpenoid from Seeds of Carapa procera Active against Breast Cancer Cell Lines.

Dioum MD, Seck M, Silvestre V, Planchat A, Loquet D, Lohard S, Barille-Nion S, Remaud GS, Robins RJ, Tea I.

Planta Med. 2016 Jul;82(11-12):967-72. doi: 10.1055/s-0042-107797. Epub 2016 May 25.

PMID:
27224268
5.

Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.

Montoir D, Barillé-Nion S, Tonnerre A, Juin P, Duflos M, Bazin MA.

Eur J Med Chem. 2016 Aug 25;119:17-33. doi: 10.1016/j.ejmech.2016.04.050. Epub 2016 Apr 22.

PMID:
27153346
6.

miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.

Das SG, Romagnoli M, Mineva ND, Barillé-Nion S, Jézéquel P, Campone M, Sonenshein GE.

Breast Cancer Res. 2016 Apr 2;18(1):40. doi: 10.1186/s13058-016-0699-z.

7.

Carcinoma-associated fucosylated antigens are markers of the epithelial state and can contribute to cell adhesion through CLEC17A (Prolectin).

Breiman A, López Robles MD, de Carné Trécesson S, Echasserieau K, Bernardeau K, Drickamer K, Imberty A, Barillé-Nion S, Altare F, Le Pendu J.

Oncotarget. 2016 Mar 22;7(12):14064-82. doi: 10.18632/oncotarget.7476.

8.

Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells.

Duy Vo D, Rouaud I, Le Devehat F, Gautier F, Barillé-Nion S, Juin P, Levoin N, Boustie J, Grée R.

Med Chem. 2016;12(5):419-25.

PMID:
26825069
9.

Survivin contributes to DNA repair by homologous recombination in breast cancer cells.

Véquaud E, Desplanques G, Jézéquel P, Juin P, Barillé-Nion S.

Breast Cancer Res Treat. 2016 Jan;155(1):53-63. doi: 10.1007/s10549-015-3657-z. Epub 2015 Dec 18.

10.

YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network.

Véquaud E, Séveno C, Loussouarn D, Engelhart L, Campone M, Juin P, Barillé-Nion S.

Oncotarget. 2015 May 30;6(15):13476-86.

11.

A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.

Levoin N, Vo DD, Gautier F, Barillé-Nion S, Juin P, Tasseau O, Grée R.

Bioorg Med Chem. 2015 Apr 15;23(8):1747-57. doi: 10.1016/j.bmc.2015.02.060. Epub 2015 Mar 6.

12.

Bcl-xL controls a switch between cell death modes during mitotic arrest.

Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, Juin P, Barillé-Nion S.

Cell Death Dis. 2014 Jun 12;5:e1291. doi: 10.1038/cddis.2014.251. Erratum in: Cell Death Dis. 2014;5:e1429.

13.

Design, synthesis and biological evaluation of new inhibitors of Bax/Bcl-xL interaction in cancer cells.

Vo DD, Gautier F, Barillé-Nion S, Juin P, Levoin N, Grée R.

Bioorg Med Chem Lett. 2014 Apr 1;24(7):1758-61. doi: 10.1016/j.bmcl.2014.02.035. Epub 2014 Feb 24.

PMID:
24602902
14.

ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis.

Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg Á, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE.

EMBO Mol Med. 2014 Feb;6(2):278-94. doi: 10.1002/emmm.201303373. Epub 2013 Dec 27.

15.

Hemisynthesis of selected embelin analogs and investigation of their proapoptotic activity against cancer cells.

Viault G, Babu KS, Gautier F, Barillé-Nion S, Juin P, Tasseau O, Grée R.

Med Chem. 2013 Dec;9(8):1028-34.

PMID:
23373598
16.

Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy.

Barillé-Nion S, Bah N, Véquaud E, Juin P.

Anticancer Res. 2012 Oct;32(10):4225-33. Review. Erratum in: Anticancer Res. 2014 May;34(5):2687.

PMID:
23060542
17.

Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5.

Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel P, Seldin ML, Sonenshein GE.

Cancer Res. 2012 Dec 1;72(23):6268-78. doi: 10.1158/0008-5472.CAN-12-2270. Epub 2012 Oct 10.

18.

Phytochemicals isolated from leaves of Chromolaena odorata: impact on viability and clonogenicity of cancer cell lines.

Kouamé PB, Jacques C, Bedi G, Silvestre V, Loquet D, Barillé-Nion S, Robins RJ, Tea I.

Phytother Res. 2013 Jun;27(6):835-40. doi: 10.1002/ptr.4787. Epub 2012 Aug 16.

PMID:
22899281
19.

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.

Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S.

Breast Cancer Res. 2012 Jun 15;14(3):R96.

20.

c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.

Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P.

Mol Cancer. 2011 Sep 7;10:110. doi: 10.1186/1476-4598-10-110.

21.

Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin.

Quillard T, Devalliere J, Chatelais M, Coulon F, Séveno C, Romagnoli M, Barillé Nion S, Charreau B.

PLoS One. 2009 Dec 11;4(12):e8244. doi: 10.1371/journal.pone.0008244.

22.

The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.

Romagnoli M, Séveno C, Wuillème-Toumi S, Amiot M, Bataille R, Minvielle S, Barillé-Nion S.

Br J Haematol. 2009 Apr;145(2):180-9. doi: 10.1111/j.1365-2141.2009.07608.x. Epub 2009 Mar 2.

PMID:
19298592
23.

Impact of XIAP protein levels on the survival of myeloma cells.

Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S.

Haematologica. 2009 Jan;94(1):87-93. doi: 10.3324/haematol.13483. Epub 2008 Nov 10.

24.

[Survivin in cancerology : molecular aspects and therapeutic applications].

Romagnoli M, Séveno C, Bataille R, Barillé-Nion S.

Med Sci (Paris). 2008 Oct;24(10):821-7. doi: 10.1051/medsci/20082410821. Review. French.

25.

Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.

Romagnoli M, Desplanques G, Maïga S, Legouill S, Dreano M, Bataille R, Barillé-Nion S.

Clin Cancer Res. 2007 Oct 15;13(20):6010-8.

26.

Significant impact of survivin on myeloma cell growth.

Romagnoli M, Trichet V, David C, Clément M, Moreau P, Bataille R, Barillé-Nion S.

Leukemia. 2007 May;21(5):1070-8. Epub 2007 Feb 22.

PMID:
17315024
27.

Cell cycle and cell death associates in western France.

Coqueret O, Barillé-Nion S, Juin P.

Cell Death Differ. 2007 May;14(5):1066-7. Epub 2007 Feb 2. No abstract available.

28.

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C.

Haematologica. 2006 Sep;91(9):1234-40. Review.

29.

Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells.

Giuliani N, Colla S, Morandi F, Barille-Nion S, Rizzoli V.

Haematologica. 2005 Feb;90(2):275-8.

30.

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R.

Cancer Res. 2004 Jan 15;64(2):772-3; author reply 774-5. No abstract available.

31.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

PMID:
14633785
32.

New insights in myeloma-induced osteolysis.

Barillé-Nion S, Bataille R.

Leuk Lymphoma. 2003 Sep;44(9):1463-7. Review.

PMID:
14565645

Supplemental Content

Loading ...
Support Center